COVID-19 Diagnostics Market Growth & Trends

The global COVID-19 diagnostics market size is expected to reach USD 24.6 billion by 2027, according to a new report by Grand View Research, Inc. It is anticipated to expand at a CAGR of 3.1% during the forecast period. An increase in the need for mass testing and efficiency in diagnosing the infection are key contributors to market growth. As the number of COVID-19 cases is exponentially rising, the need to develop rapid and easy-to-use diagnostic and serology tests is also increasing. This has created opportunities for emerging players and new market entries, thereby driving market revenue.

Large-scale operational entities in Sweden, such as Tele2, H&M, and Spotify are engaged in mass testing for distinguishing the staff tested positive from uninfected. In addition, key players are constantly accelerating the production and supply of diagnostic tests to keep pace with the increasing need for disease containment. For instance, in May 2020, Roche introduced an antibody test which is recognized as 100% accurate by Public Health England.

Exploring the potential of novel molecular technologies in the scaling-up of coronavirus testing is expected to offer a significant momentum to the expansion of COVID-19 diagnostics space. For instance, CRISPR-a gene editing technology-has recently made its way into the coronavirus testing market. This gene-editing technology enables detection of SARS-CoV-2 genes, via a protein, namely, CRISPR-Cas12. Acknowledging the potential of this technology in diagnosing coronavirus patients, the Food and Drug Administration (FDA) recently approved the CRISPR test for coronavirus patients in the U.S. This diagnostic kit has been approved under the provisions of emergency use.

The expanding pool of startup companies actively operating in the market for COVID-19 diagnostics is also expected to intensify market participant competition. This trend has been prominently observed in the Asia Pacific region, contributing to the fast-paced growth expected to be witnessed by this region through 2021-2027. Some of the startup manufacturers of novel COVID-19 tests include Mylab, DNA Xperts Private Limited, Rokid, Bione, and SD Biosensor.

COVID-19 Diagnostics Market Report Highlights

  • Diagnostic service is estimated to capture the maximum revenue share owing to the introduction of policies and mandates to conduct testing at large scale globally
  • The nasopharyngeal swabs segment is estimated to dominate the market in 2020 with a revenue share of 48%, followed by an Oropharyngeal (OP) swab. Nasopharyngeal swabs are the gold standard for COVID-19 sample collection; both oropharyngeal and nasopharyngeal swabs are largely employed in PCR testing. This has propelled the expansion of point-of-care COVID-19 testing market space, which has contributed to the segment’s fast-paced growth through 2021 to 2027
  • The increasing popularity of at-home testing and handheld instruments targeted toward combating the shortage of coronavirus test kits has been witnessed. This is expected to result in the lucrative growth of Point-of-Care (POC) testing during the forecast period
  • Laboratories are estimated to be the key revenue contributing end-users owing to the primary role of laboratories in sample testing for suspected individuals
  • Asia Pacific is projected to dominate the market for COVID-19 diagnostics in 2020 with a revenue share of around 37% and is expected to maintain this dominance during the forecast period. This is attributed to the robust funding for fast-track studies pertaining to clinical validation of rapid testing as well as the rapid launch of novel products. Robust government initiatives aimed at increasing the number of operational laboratories dedicated to coronavirus testing across Asian countries are set to propel the market growth